Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

Angela Read thought she had a sinus infection, soon she discovered her condition was much more serious. She's grateful to the ...

Ultra-long-acting treatment could reshape respiratory care as EU regulators back GSK's high-stakes depemokimab ahead of 2026 ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

Europe’s drug regulator backed GSK Plc’s drug to treat severe asthma or a common nasal condition, in the first such recommendation globally for a medicine that is pegged to become a blockbuster.

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments ...

GSK expects the European Commission to decide on approvals for both depemokimab and Nucala in the first quarter of 2026. GSK shares were 0.1% higher at 1,822.50 pence each on Friday afternoon in ...

Whether it's a fresh summer breeze, melted chocolate, or your favourite perfume, different smells can mean a lot to us. But what if you woke up one day unable to smell anything? Anosmia is the loss of ...